Company Description
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally.
It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths.
The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets.
This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
| Country | United States |
| Founded | 1979 |
| IPO Date | Mar 4, 1998 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 389 |
| CEO | Gary Maharaj |
Contact Details
Address: 9924 West 74th Street Eden Prairie, Minnesota 55344-3523 United States | |
| Phone | 952 500 7000 |
| Website | surmodics.com |
Stock Details
| Ticker Symbol | SRDX |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000924717 |
| CUSIP Number | 868873100 |
| ISIN Number | US8688731004 |
| Employer ID | 41-1356149 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Gary R. Maharaj | Chief Executive Officer, President and Director |
| Timothy J. Arens | Senior Vice President of Finance and Information Technology and Chief Financial Officer |
| Gordon S. Weber J.D. | Senior Vice President of Legal, General Counsel and Secretary |
| Charles W. Olson | Senior Vice President and President of Medical Device Coatings |
| Teryl L. W. Sides | Senior Vice President and President of Vascular Interventions |
| John D. Manders | Corporate Controller, Vice President of Finance and Principal Accounting Officer |
| Joel Suiter | Director of Corporate Development |
| Joseph J. Stich | Senior Vice President of Human Resources and President of In Vitro Diagnostics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 19, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 26, 2024 | 144 | Filing |
| Nov 20, 2024 | 10-K | Annual Report |
| Nov 15, 2024 | SCHEDULE 13G | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |